| Literature DB >> 29397389 |
Harikesh Dubey1, Kavita Gulati1, Arunabha Ray1.
Abstract
Alzheimer's disease (AD) is one of the most common neurodegenerative disorders mainly affecting elderly people. It is characterized by progressive loss of memory and cognitive function. More than 95% of AD cases are related to sporadic or late-onset AD (LOAD). The etiology of LOAD is still unclear. It has been reported that environmental factors and epigenetic alterations play a significant role in AD pathogenesis. Furthermore, recently, genome-wide association studies (GWAS) identified 10 novel risk genes: ABCA7, APOE, BIN1, CD2AP, CD33, CLU, CR1, MS4A6A, MS4A4E, and PICALM, which play an important role for LOAD. In this review, the therapeutic approaches of AD by epigenetic modifications have been discussed. Nowadays, HDAC inhibitors have clinically proven its activity for epigenetic modifications. Furthermore, we try to establish the relationship between HDAC inhibitors and above mentioned LOAD risk genes. Finally, we are hoping that this review may open new area of research for AD treatment.Entities:
Keywords: Alzheimer’s disease; GWAS; HDAC inhibitors; LOAD; epigenetic modification
Mesh:
Substances:
Year: 2018 PMID: 29397389 DOI: 10.1515/revneuro-2017-0049
Source DB: PubMed Journal: Rev Neurosci ISSN: 0334-1763 Impact factor: 4.353